Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...
Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of ...
Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...
An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive ...
It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly. Testing for myeloid ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Durasert, a 3-year treatment for posterior segment ...
Expert Rev Ophthalmol. 2008;3(4):449-456. Infliximab is a monoclonal human-murine chimeric antibody. Since it is a chimeric antibody, infliximab is usually given concomitantly with a second agent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results